



**WHAT IS CLAIMED IS:**

1. Substantially pure ETM-305, having the following structure:




ETM 305

2. Substantially pure ETM-204, having the following structure:



ETM 204

3. Substantially pure ETM-775 having the following structure:



ETM 775

RECEIVED U.S. PATENT OFFICE

4. A method of treating mammalian leukemia in patients in need of such treatment, said method comprising administering an effective amount of ETM-305 to said patient in unit dosage form.

5. A method of treating mammalian leukemia in patients in need of such treatment, said method comprising administering an effective amount of ETM-775 to said patient in unit dosage form.

6. A method of treating mammalian lung carcinoma in patients in need of such treatment, said method comprising administering an effective amount of ETM-305 to said patient in unit dosage form.

7. A method of treating mammalian lung carcinoma in patients in need of such treatment, said method comprising administering an effective amount of ETM-775 to said patient in unit dosage form.

8. A method of treating mammalian colon adenocarcinoma in patients in need of such treatment, said method comprising administering an effective amount of ETM-305 to said patient in unit dosage form.

9. A method of treating mammalian colon adenocarcinoma in patients in need of such treatment, said method comprising administering an effective amount of ETM-775 to said patient in unit dosage form.

10. A method of treating mammalian malignant melanoma in patients in need of such treatment, said method comprising administering an effective amount of ETM-305 to said patient in unit dosage form.

11. A method of treating mammalian malignant melanoma in patients in need of such treatment, said method comprising administering an effective

amount of ETM-775 to said patient in unit dosage form.

12. A pharmaceutical composition comprising ETM-305 and a pharmaceutically acceptable carrier, diluent or excipient.

13. A pharmaceutical composition comprising ETM-775 and a pharmaceutically acceptable carrier, diluent or excipient.

14. A method of assaying the human cytochrome CYP3A4 metabolism of ecteinascidin 743, comprising monitoring a test sample for the presence of one or more metabolites selected from the group consisting of ETM-204, ETM-305 and ETM-775.

RECEIVED U.S. PATENT & TRADEMARK OFFICE